The objectives of this survey are: 1) To examine the safety/efficacy profile of Januvia in Korean participants, and 2) To identify factors that might have an influence on the safety and efficacy profile of Januvia in Korean participants. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.
Study Type
OBSERVATIONAL
Enrollment
3,483
Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
Sulfonylurea administered in general use according to the local label
Insulin administered in general use according to the local label
Percentage of participants with any adverse experience
Time frame: up to 14 days following cessation of treatment
Mean change in Hemoglobin A1c (HbA1c)
Time frame: 12 weeks ± 2 weeks and 24 weeks ± 2 weeks after first treatment
Mean change in fasting plasma glucose (FPG)
Time frame: 12 weeks ± 2 weeks and 24 weeks ± 2 weeks after first treatment
Mean change in 2hr-postprandial glucose (PPG)
Time frame: 12 weeks ± 2 weeks and 24 weeks ± 2 weeks after first treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.